Phase 3 N=746 Capsaicin + Diclofenac Gel in Acute Back Pain or Neck Pain
Acute Pain
Primary: Change in POM Between Baseline and Day 2 Evening, 1 Hour After Drug Application — -2.45; -3.26; -2.33; -3.05 Units on a scale — p=0.0303
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=224 Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease in Children Aged Between 6 and 9 Years — 290.4; 719.2; 381.2; 393.9…
N/A N=282 A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial
Primary Open Angle Glaucoma (POAG)
Primary: 5-year Annualized Rate (Percentage) of Sight-threatening Adverse Events, by Treatment Group — 0.19; 0.30 rate (percentage) of adverse events
N/A N=292 Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Primary: Number of Participants Who Had One or More Adverse Events (AE) and Serious Adverse Events (SAE) — 238; 97 Participants
N/A N=11,001 Real World Glycemic Effectiveness of Linagliptin
Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Hemoglobin (HbA1c) Across Age Categories — -0.51; -0.65; -0.59; -0.43 Percentage (%)
Phase 3 N=179 Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension
Arterial Hypertension
Primary: Change in Systolic Blood Pressure (SBP) After 12 Weeks of Treatment — 152.9; 151.9; -25.2; -24.3 mm Hg — p==0.390
N/A N=160 Novel Angioplasty Using Coronary Accessor
Patency of the Radial Artery
Primary: Number of Patients With Radial Artery Occlusion — 3; 0 Participants
Phase 2 N=68 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Acute Myeloid Leukemia · Myelodysplastic Syndromes · Agnogenic Myeloid Metaplasia
Primary: Participant Response Rate — 1; 0; 1; 0 Participants
Phase 4 N=37 Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation
Hyperlipidemia
Primary: Flow-mediated Dilation (FMD) With Fasting State at Baseline, Week 4 and Week 8 — 6.71; 5.85; 5.85; 3.15 Percentage of dilation
Phase 2 N=57 Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Disease Control Rate (DCR) After 6 Months — 73.5 percentage of subjects
N/A N=32 Evaluation of a Shelter-Based Diet and Physical Activity Intervention for Homeless Adults
Dietary Modification · Physical Activity
Primary: Automated Self-Administered 24-Hour Dietary Recall: Fruit/Vegetable, Cups — 2.08; 3.56 cups — p=.18
N/A N=311 Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
Chronic Hepatitis C, Genotype 1 or 4
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 87.7; 93.8 percentage of participants
Phase 2 N=19 Development and Pilot Evaluation of a Web-supported Programme of Constraint Induced Therapy Following Stroke (LifeCIT)
Stroke
Primary: Change in Upper Limb Impairment: Motor Activity Log (MAL) Amount of Use (AOU) — 1.02; 0.06; 0.60; 0.29 units on a scale
Phase 2 N=21 A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia
Cytopaenia
Primary: Hematological Response at Week 26 — 47.6 Percentage of participants
N/A N=312 The Gore SCAFFOLD Clinical Study
Carotid Artery Disease · Carotid Artery Stenosis
Primary: Number of Participants Who Experienced Major Adverse Events (MAE) at One Year — 11 Participants — p=<0.00001